NKG2D-Fc Fusion Protein QEQ278

**Semantic type:** Pharmacologic Substance

**Definition:** A Fc fusion protein containing human natural-killer group 2, member D receptor protein (NKG2D or KLRK1; natural killer cell activating receptor group 2D) fused to a Fc fragment, with potential immunomodulating and antineoplastic activities. Upon administration, NKG2D-Fc fusion protein QEQ278 specifically targets and binds to tumor cells expressing NKG2D ligands (NKG2DL) and neutralizes soluble NKG2DL. This may re-activate natural killer (NK) cells and cytotoxic T-lymphocytes responses and may induce antibody-dependent cell-mediated cytotoxicity (ADCC) and antibody-dependent cellular phagocytosis (ADCP) in NKG2DL-expressing tumor cells. Ligands for NKG2D, such as MHC class I chain-related protein A (MICA), MICB, and members of the UL16-binding proteins (ULBP)/retinoic acid early transcript 1 (RAET1) family, are overexpressed on infected cells and most cancer cell types, but are not expressed on most normal, healthy cells. NKG2D functions as an activating and costimulatory receptor and plays a key role in immunosurveillance.

**Synonyms:** - QEQ 278 - QEQ-278 - QEQ278